Publications by authors named "M Merz"
Article Synopsis
- * Findings indicated that patients' median age at first ASCT has increased, while the use of tandem ASCT decreased, and there were improved survival rates across all age groups, especially older patients.
- * Careful patient selection is crucial for tandem ASCT, as it is less beneficial for those with certain conditions (ISS III and renal impairment), older patients, and those who achieve complete response after initial ASCT.
Article Synopsis
- CAR T-cell therapy shows strong initial results for treating relapsed refractory multiple myeloma, but most patients eventually relapse, often within 5 months.
- In a study of 139 patients who relapsed after CAR T-cell therapy, different salvage therapies were analyzed, revealing that bispecific antibodies, like talquetamab and teclistamab, had the best overall and complete response rates.
- The presence of extramedullary disease at relapse was linked to poorer outcomes, but bispecific antibodies improved survival rates, suggesting they should be the standard treatment for patients relapsing after CAR T-cell therapy.
The high-voltage oxygen redox activity of Li-rich layered oxides enables additional capacity beyond conventional transition metal (TM) redox contributions and drives the development of positive electrode active materials in secondary Li-based batteries. However, Li-rich layered oxides often face voltage decay during battery operation. In particular, although Li-rich positive electrode active materials with a high nickel content demonstrate improved voltage stability, they suffer from poor discharge capacity.
View Article and Find Full Text PDFEstablishing a strategy for sequencing of T cell redirecting therapies for relapsed/refractory multiple myeloma (RRMM) is a pressing clinical need. We longitudinally tracked the clinical and immunological impact of bispecific T cell engaging antibodies (BsAb) as bridging therapy (BT) to subsequent BCMA-directed CAR-T cell therapies in 52 RRMM patients. BsAbs were a potent and safe option for BT, achieving the highest overall response rate (100%) to BT compared to chemotherapy, anti-CD38 or anti-SLAMF7 antibody based regimens (46%).
View Article and Find Full Text PDFArticle Synopsis
- * Results indicate that age does not significantly impact progression-free and overall survival rates, although patients aged 70 and older experienced slightly longer hospital stays.
- * The findings suggest that HDT/ASCT is both safe and effective for elderly patients, emphasizing that patient selection should focus on biological age and health status rather than just chronological age.